Pages that link to "Q33364244"
Jump to navigation
Jump to search
The following pages link to Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma (Q33364244):
Displaying 50 items.
- The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive? (Q26772907) (← links)
- Modulatory effects of bortezomib on host immune cell functions (Q26795618) (← links)
- Advances in the understanding of mechanisms and therapeutic use of bortezomib (Q26849940) (← links)
- Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics (Q27851412) (← links)
- Development and characterization of a Mantle Cell Lymphoma Cell Bank in the American Type Culture Collection (Q27913808) (← links)
- Mantle cell lymphoma: observation to transplantation (Q28256317) (← links)
- PERK Integrates Oncogenic Signaling and Cell Survival During Cancer Development (Q28397172) (← links)
- The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders. (Q30248842) (← links)
- Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B (Q33303627) (← links)
- A phase II study of bortezomib in the treatment of metastatic malignant melanoma (Q33366244) (← links)
- Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. (Q33375800) (← links)
- A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors (Q33378902) (← links)
- Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network (Q33379947) (← links)
- Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma (Q33381780) (← links)
- Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma (Q33381844) (← links)
- Targeting the UPS as therapy in multiple myeloma (Q33384287) (← links)
- Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA (Q33385353) (← links)
- Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma (Q33385670) (← links)
- Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). (Q33391725) (← links)
- Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma (Q33393436) (← links)
- Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma (Q33394873) (← links)
- Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study (Q33396465) (← links)
- A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma (Q33396522) (← links)
- Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study (Q33404090) (← links)
- Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (Q33414243) (← links)
- A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma (Q33414307) (← links)
- Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma (Q33416533) (← links)
- Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma (Q33418257) (← links)
- 2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma (Q33420981) (← links)
- Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma (Q33427510) (← links)
- A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma (Q33443555) (← links)
- Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches (Q33586239) (← links)
- Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma (Q33669018) (← links)
- Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysis (Q33713106) (← links)
- BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future (Q34041311) (← links)
- Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma (Q34059058) (← links)
- Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma (Q34129360) (← links)
- A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma (Q34134986) (← links)
- The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors (Q34218976) (← links)
- The treatment of traumatic brain injury with velcade (Q34254813) (← links)
- A novel insertion ins(18;5)(q21.1;q31.2q35.1) in acute myeloid leukemia associated with microdeletions at 5q31.2, 5q35.1q35.2 and 18q12.3q21.1 detected by oligobased array comparative genomic hybridization (Q34268171) (← links)
- Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline. (Q34335445) (← links)
- Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma (Q34372977) (← links)
- Targeted therapy in lymphoma (Q34413686) (← links)
- Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells (Q34541718) (← links)
- Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation (Q34542087) (← links)
- A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group (Q34585047) (← links)
- Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma (Q34606802) (← links)
- Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. (Q34608608) (← links)
- Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent (Q34610605) (← links)